Quick Answer
Centessa Pharmaceuticals plc reported Total Revenue of $15.00 million for fiscal year 2025.
Centessa Pharmaceuticals plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $15.00M | $0.00 -100.0% |
$6.85M | $0.00 | — | — |
| Net Income | -$197.53M +16.2% |
-$235.76M -56.0% |
-$151.09M +30.1% |
-$216.21M -25980.5% |
-$829.0K +92.2% |
-$10.66M -110.7% |
| Diluted EPS | -$1.46 +29.1% |
-$2.06 -31.2% |
-$1.57 +32.0% |
-$2.31 +54.4% |
-$5.07 | — |
| Total Assets | $687.50M +19.2% |
$576.80M +60.1% |
$360.25M -18.9% |
$444.31M -29.4% |
$629.63M +5273.7% |
$11.72M |
| Cash and Equivalents | $61.30M -84.0% |
$383.22M +199.3% |
$128.03M -67.5% |
$393.64M -33.9% |
$595.08M +8134.1% |
$7.23M |
| Long-Term Debt | $110.09M +1.1% |
$108.94M +43.9% |
$75.70M +8.5% |
$69.80M -7.8% |
$75.70M | $0.00 |
| Stockholders Equity | $526.86M +31.2% |
$401.55M +70.0% |
$236.24M -29.7% |
$336.17M +7327.9% |
-$4.65M | — |
| Operating Income | -$207.69M -3.3% |
-$201.06M -17.4% |
-$171.28M +19.3% |
-$212.26M -27008.9% |
-$783.0K +92.5% |
-$10.44M -106.6% |
| Shares Outstanding | 149.23M +12.5% |
132.63M +34.3% |
98.77M +4.1% |
94.84M +5.4% |
89.99M | 0 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$54.89M | -29.0% | -9.0% |
| Diluted EPS | September 30, 2025 | -$0.41 | -10.8% | -7.9% |
| Total Assets | September 30, 2025 | $448.30M | -26.5% | -8.9% |
| Cash and Equivalents | September 30, 2025 | $50.81M | -87.1% | +14.8% |
| Long-Term Debt | September 30, 2025 | $109.82M | +45.1% | +0.2% |
| Stockholders Equity | September 30, 2025 | $301.57M | -39.6% | -12.6% |
| Operating Income | September 30, 2025 | -$53.79M | -15.9% | +1.6% |
| Shares Outstanding | September 30, 2025 | 134.42M | +2.1% | +0.4% |
- Centessa Pharmaceuticals plc reported Total Revenue of $15.00 million for fiscal year 2025.
- Centessa Pharmaceuticals plc reported Net Income of -$197.53 million for fiscal year 2025.
- Centessa Pharmaceuticals plc showed an increase of +16.2% in Net Income compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Diluted EPS of $1.46 per share (loss) for fiscal year 2025.
- Centessa Pharmaceuticals plc showed an increase of +29.1% in Diluted EPS compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Total Assets of $687.50 million for fiscal year 2025.
- Centessa Pharmaceuticals plc showed an increase of +19.2% in Total Assets compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Cash and Equivalents of $61.30 million for fiscal year 2025.
- Centessa Pharmaceuticals plc showed a decrease of -84.0% in Cash and Equivalents compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Long-Term Debt of $110.09 million for fiscal year 2025.
- Centessa Pharmaceuticals plc showed an increase of +1.1% in Long-Term Debt compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Stockholders Equity of $526.86 million for fiscal year 2025.
- Centessa Pharmaceuticals plc showed an increase of +31.2% in Stockholders Equity compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Operating Income of -$207.69 million for fiscal year 2025.
- Centessa Pharmaceuticals plc showed a decrease of -3.3% in Operating Income compared to the prior fiscal year.
- Centessa Pharmaceuticals plc reported Shares Outstanding of 149.23 million shares for fiscal year 2025.
- Centessa Pharmaceuticals plc showed an increase of +12.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: